Kala Pharmaceuticals, Inc. (KALA)
| Market Cap | 344.54M |
| Revenue (ttm) | 8.56M |
| Net Income (ttm) | -112.78M |
| Shares Out | 61.66M |
| EPS (ttm) | -1.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $5.01 |
| Previous Close | $5.47 |
| Change ($) | -0.46 |
| Change (%) | -8.41% |
| Day's Open | 5.43 |
| Day's Range | 4.90 - 5.53 |
| Day's Volume | 2,738,081 |
| 52-Week Range | 4.90 - 14.68 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
Kala Pharma (KALA) delivered earnings and revenue surprises of 3.92% and -10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Kala Pharmaceuticals (NASDAQ:KALA) fell 0.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 9.26% over the past year to ($0.49), wh...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
Kala Pharma (KALA) delivered earnings and revenue surprises of -19.57% and -6.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...
Kala Pharma (KALA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
The Play On Kala Pharmaceuticals
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Compan...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2020 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
Good news from the FDA translated to bad news for Kala's share price.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases ...
Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.
Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2020 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (KALA) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for May 26th
Is (KALA) Outperforming Other Medical Stocks This Year?
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2020 Results - Earnings Call Transcript
Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Kala Pharmaceuticals (NASDAQ:KALA) were flat in pre-market trading after the company reported Q1 results.
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.
Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.
Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
Kala Pharmaceuticals Looks To Keep Rally Going
About KALA
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs co... [Read more...]
| Industry Biotechnology | IPO Date Jul 20, 2017 |
| CEO Mark Iwicki | Employees 188 |
| Stock Exchange NASDAQ | Ticker Symbol KALA |
Financial Performance
In 2020, KALA's revenue was $6.36 million, an increase of 4.74% compared to the previous year's $6.07 million. Losses were -$104.33 million, 10.6% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for KALA stock is "Buy." The 12-month stock price forecast is 20.33, which is an increase of 305.79% from the latest price.